MiNA Completes Exclusive License Agreement with University of California San Francisco

November 18, 2014 08:00 AM Eastern Standard Time

LONDON--()--MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today that it has completed an exclusive license agreement with The Regents of the University of California relating to intellectual property rights developed by the Li lab at UC San Francisco (UCSF).

"This license extends MiNA's dominant intellectual property position in RNA activation at a time when MiNA is advancing its technology platform into novel therapies," said Robert Habib, Chief Executive Officer of MiNA Therapeutics.The exclusive license complements MiNA's fundamental intellectual property portfolio that broadly covers RNAa therapeutics, including small activating RNAs, or saRNAs, the molecules that mediate RNAa.

"We are delighted that MiNA Therapeutics is developing saRNA therapeutics," said Long-Cheng Li, M.D., Associate Professor in the UCSF Department of Urology and an inventor on the Li patent estate. "Our hope is that these small activating RNAs will not only shed further insight into disease, but also offer the potential to target a broad range of untreatable conditions."

About MiNA Therapeutics

MiNA Therapeutics is a biopharmaceutical company pioneering the discovery and development of a new class of medicines that selectively up-regulate proteins inside patient cells. MiNA's proprietary RNA activation (RNAa) technology platform enables up-regulation of beneficial proteins by the selective and long lasting transcriptional activation of a target gene. RNAa has unique potential to target diseases that are untreatable with today's conventional medicine. MiNA's novel drugs, termed small activating RNAs (saRNAs), leverage existing RNA delivery technologies to accelerate the development of drug candidates. The company is developing MTL-CEBPA, a first in class treatment for advanced liver cancer. MiNA was founded in 2008 by pioneering researchers John Rossi, Nagy Habib and Pal Saetrom. The company is privately held and located in London, United Kingdom. To learn more visit www.minatx.com.

About UC San Francisco

The UCSF Office of Innovation, Technology & Alliances coordinates UCSF's efforts in forging collaborations and licensing technologies that translate cutting-edge science on campus into therapies and products that directly benefit patients worldwide.

UCSF is the nation's leading university exclusively focused on health. Now celebrating the 150th anniversary of its founding as a medical college, UCSF is dedicated to transforming health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with world-renowned programs in the biological sciences, a preeminent biomedical research enterprise and two top-tier hospitals, UCSF Medical Center and UCSF Benioff Children's Hospital San Francisco. Please visit www.ucsf.edu.

UC Disclaimer

The information stated above was prepared by MiNA Therapeutics and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of MiNA, or any of its products, by The Regents of the University of California, its officers, agents and employees.


MiNA Therapeutics
Robert Habib, CEO
+44 203 727 2604
[email protected]